retatrutide dosage in clinical trials trial dosing frequency microdosing: guide to split protocols and schedules The Retatrutide Chart: A – retatrutide dosage clinical trial retatrutide

TB-500 has some GI data (thymosin beta-4 has shown effects in colitis models), but the evidence base isn't comparable to BPC-157's extensive GI portfolio

The SURMOUNT-1 Phase 3 trial published in The New England Journal of Medicine enrolled 2,539 adults with obesity and demonstrated mean body weight reduction of 20.9% at 72 weeks on tirzepatide 15mg weekly versus 3.1% placebo

doi: 10.1016/j.anai.2020.08.002 14

From January 2023 to June 2024, all patients underwent a transurethral endoscopic procedure during which they were given intravesical injections of 1 mg BPC-157, placed in 10 spots (total of 10 mg) in the uroepithelium of the bladder wall